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 Sterol regulatory element binding 
proteins (SREBPs) regulate the expression 
of a number of enzymes which catalyze 
the synthesis of fatty acids, cholesterol, 
triglycerides, and phospholipids. 
SREBP1c is the most relevant isoform in 
the adult liver and its expression is 
controlled by the nutritional state. 
Transcriptional regulation studies into the 
SREBP1c gene, performed in the last few 
years, have improved our knowledge of 
the variability of signals that converge on 
its promoter region. Insulin, cholesterol 
derivatives, T3 and other endogenous 
molecules have been demonstrated to 
regulate the SREBP1c expression, 
particularly in rodents. The present study 
aimed to perform a detailed analysis of 
the human SREBP1c gene promoter 
structure in liver cells by focusing on 
responses to diverse metabolic signals. 
Serial deletion and mutation assays reveal 
that both SREBP (SRE) and LXR (LXRE) 
response elements are involved in  
SREBP1c transcription regulation 
mediated by insulin and cholesterol 
derivatives. We discovered that 
peroxisome proliferation-activated 
receptor alpha (PPARα) agonists enhance 
the activity of the SREBP1c promoter, a 
DR1 element, at -453 in the human 
promoter, involved in this activation. 
Moreover, PPARα agonists act in 
cooperation with LXR or insulin to induce 
lipogenesis. Collectively, our results 
identify PPARα as a novel regulatory 
factor in SREBP1c regulation which plays 
a relevant role in the interplay between 
lipids and insulin metabolic regulation. 
 The prevalence of overweight and 
obesity is increasing worldwide at an alarming 
rate. An excess amount of body fat not only leads 
to reduced quality of life and immense 
healthcare-associated costs, but also increases 
risk of death. Indeed, obesity has been related to 
a number of cardiovascular and metabolic 
disorders such as hypertension, type 2 diabetes, 
hyperinsulinemia, dyslipidemia and 
atherosclerosis by defining features of the 
metabolic syndrome. Beyond obesity and a 
number of independent factors, the other 
etiological factor of metabolic syndrome is 
insulin resistance, commonly considered to be of 
greater priority in pathogenesis (1,2).  
 The discovery of Sterol regulatory 
element binding proteins (SREBP) was critical 
for our understanding of hepatic cholesterol 
homeostasis. SREBP1c, one of three SREBPs 
members of the basic helix-loop-helix (bHLH) 
family of transcription factors, is essential for the 
genomic actions of insulin on both carbohydrate 
and lipid metabolism (3), and plays a central 
role in the molecular biochemistry of metabolic 
syndrome. The SREBP1c expression is 
controlled by nutritional status. Fasting lowers 
SREBP1c mRNA and protein levels, whereas 
they are strongly induced in a fed state, followed 
by a compatible pattern of nutritional changes in 
lipogenic genes (4). Accordingly, changes in this 
transcription factor activity may be the key to 
linking insulin resistance with other obesity-
associated metabolic disorders.  
 Liver X receptors (LXR) belong to the 
nuclear hormone receptor superfamily. The LXR 
subfamily consists of two members; LXRα and 
LXRβ; which are activated by oxysterols. The 
LXRα expression pattern is mainly restricted to 
the liver, adipocytes, the small intestine and 
macrophages, whereas LXRβ is expressed 
ubiquitously (5). LXRs directly bind the cis 
elements in the Srebp1c promoter as 
heterodimers with RXR, leading to 
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transcriptional activation. Lipogenesis regulation 
by LXR is mediated through this effect on the 
SREBP1c expression (6).  
 Along with LXR, other members of this 
superfamily of nuclear hormone receptors, 
peroxisome proliferator-activated receptors 
(PPARs) play a major role in lipid metabolism. 
The PPARs family is represented by three 
members: PPARα, the predominant form in the 
liver, PPARδ, and PPARγ. Different PPARs can 
be considered key messengers responsible for the 
translation of nutritional, pharmacological and 
metabolic stimuli into changes in the expression 
of those genes specifically involved in lipid 
metabolism (7). Like LXRs, activated PPARs 
also heterodimerize with RXR and alter the 
transcription of target genes. These heterodimers 
bind to specific peroxisome proliferator response 
elements (PPRE) consisting of a direct repeat of 
a hexameric DNA core recognition motif spaced 
by one nucleotide (8). The overexpression of 
PPARα in HEK293 cells has been shown to 
inhibit mouse Srebp1c promoter activity through 
competition with LXR/RXR heterodimerization 
(9). Thus, hepatic lipid homeostasis is a result of 
a complex crosstalk between a number of 
transcription factors, including LXR, PPARs and 
SREBPs. 
 In order to understand the molecular 
mechanism behind the nutritional regulation of 
the SREBP1c expression, the Srebp1c gene 
rodent promoter and, to a much lesser extent, the 
human regulatory region, has been previously 
characterized (10,11). In the proximal region of 
the mice Srebp1c promoter, SP1, NFY, USF, 
SREBP and LXR-binding sites have been 
identified (6,12). An SRE element together with 
two LXREs motifs have proved indispensable for 
the insulin response (13). The sequence of the rat 
Srebp1c proximal promoter is 97% identical to 
its murine counterpart (14). Experiments carried 
out in Marshall B. Elam’s laboratory have 
revealed that at least four unique transcription 
factor-binding elements recognized by LXRα, 
SREBP1, NFY and SP1 constitute the insulin-
response unit of the rat Srebp1c promoter 
(14,15). 
 Sequence alignments show that the 
human SREBP1c promoter presents only 42.0% 
similarity to the mouse promoter, suggesting that 
promoters might be regulated by different 
pathways and mechanisms. In the present study, 
we extensively characterized the human 
proximal SREBP1c promoter by identifying the 
nutritional regulation mechanism in liver cells. 
Moreover, we identified a PPRE element in the 
proximal human sequence. In vitro and in vivo 
studies show the direct interaction of the PPAR 
receptor with the human SREBP1c promoter, and 
propose a novel aspect of the network of 
transcription factors regulating human fatty acid 
metabolism. 
 
EXPERIMENTAL PROCEDURES 
 
Plasmids. A DNA fragment containing 1801 bp 
corresponding to the 5’ upstream region of the 
human SREBP1c gene was amplified by PCR 
and cloned into the pCR2.1-TOPO vector 
(Invitrogen) to construct pPro1c-TOPO. A 1564 
bp fragment was obtained by NcoI digestion and 
subcloned in the NcoI site of pGL3-basic 
luciferase vector (Promega) to construct the -
1564/+1-luc vector. The -520/+1-luc vector was 
prepared by PCR from the -1564/+1-luc vector 
using the forward primer 5’-
GGAGGGTACCAGGCTCGCTCAGGGTGCC
AGC-3’ and the reverse primer GLprimer2 
(Promega) to be then inserted into the KpnI/NcoI 
site of the pGL3-basic vector. -310/+1-luc was 
prepared by XhoI digestion and re-ligation from 
1564/+1-luc. Mutagenesis was performed by 
means of the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA. USA) 
using pPro1c-TOPO as a template. All the 
constructions were confirmed by nucleotide 
sequencing.  The expression vectors pCMX-
PPARα, pCMX-LXRα, pCMX-LXRβ and 
pCMX-RXRα were obtained from Dr. Antonio 
Castrillo (Facultad de Medicina, Universidad de 
Las Palmas, Las Palmas de Gran Canaria, Spain). 
  
Cell culture and luciferase assay. Rat and mouse 
hepatocytes in primary culture were prepared 
from adult rats or mice by collagenase perfusion 
(16) and seeded in Williams’ E medium, 
supplemented with glutamine, 100 nM insulin, 1 
M dexametasone, 5% FBS and antibiotics. 
Transfection assays were performed using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA. 
USA) in 6-well culture dishes with 3.8 g of 
SREBP1c reporter plasmids and 200 ng of 
Renilla luciferase vector (pRL-TK) 6 h after 
seeding. At 16 h post-transfection, hepatocytes 
were left for 24 h in Basal Induction Medium 
(Williams’ E, supplemented with glutamine, 
0.75% BSA, 100 nM dexametasone and 20 mM 
glucose). When indicated, cells were treated 
with: a) 100 nM insulin, b) 10 M or 10 nM 
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TO901317 c) 30 M WY14643, and d) 1 M 
GW7647. In some experiments, cells were co-
transfected with 200 ng of the indicated 
expression vector, while the pCMX empty vector 
was used to normalize the amount of DNA. 
Transactivation activities were measured at 24 h 
post-transfection in a Wallac 1420 VICTOR 
luminometer according to the technical manual 
for the Dual-Luciferase Reporter Assay System 
(Promega). 
 Human hepatocytes were prepared from 
the liver biopsies obtained from patients 
submitted to a surgical resection of a liver tumor 
after obtaining patients’ written consent.  
Hepatocytes isolation was based on the two-step 
collagenase procedure (17). Cell viability was 
consistently >85%, as determined by trypan blue 
exclusion. Hepatocytes (8 × 106 cells; 150,000 
cells/cm2) were seeded at confluence on type I 
collagen-coated dishes (Iwaki, Gyouda, Japan), 
and maintained in a DMEM-Ham-F12:William’s 
E (1:1) medium supplemented with 26 mM 
NaHCO, 15 mM HEPES, 0.29 g/L glutamine, 50 
mg/L vitamin C, 0.04 mg/L dexametasone, 2 
mg/L insulin, 200 µg/L glucagon, 50 mg/L 
transferrin and 4 ng/L ethanolamine containing 
5% fetal calf serum for 12 h. Afterward, the 
medium was removed and replaced with a fresh 
culture medium supplemented, when indicated,  
with: a) 100 nM insulin, b) 10 M or 10 nM 
TO901317, c) 50 M WY14643, and d) 1 M 
GW7647. 
 
Electrophoretic Mobility Shift Assays. EMSAs 
were performed using double-stranded DNA 
oligonucleotides end-labeled with [γ-32P]dATP. 
The oligonucleotides corresponding to the DR1 
binding site (5’-
CCCTTCGTTAAAGGGTCAAAGCAGAGAA
GTCCTGGCCC-3’), the LXRE1 binding site 
(5’-
GGAGCTGAGGGCCAGTGACCGCCAGTAA
CCCCGGCAGACGCTGG-3’) and the LXRE2 
binding site (5’-
CGGGTTAAAGGCGGACGTCCGCTAGTAA
CCCCAACCCCATTCAGC-3’) were annealed 
with the complementary sequence by incubation 
at 85ºC for 10 min in 70 mM Tris-HCl pH 7.5; 
13 mM MgCl; 1.3 mM EDTA; 1.3 mM 
spermidine and 6.7 mM DTT with overnight 
cooling. A 300 ng aliquot of the probe was 
labeled with 20 units of T4 polynucleotide-
kinase in the presence of 40 μCi [γ-32P]dATP at 
a final volume of 10 μl for 30 min at 37ºC and 
purified in Sephadex G25 columns. Binding 
reactions were carried out for 20 min at room 
temperature using in vitro translated human 
PPARα, LXRα and RXRα prepared with the 
TNT T7-coupled reticulocyte lysate system 
(Promega), 9 fmol of probe, and 2 μg dI/dC in 
the binding buffer (20 mM HEPES pH 8.0, 0.1 
mM EDTA, 50 mM ClNA, 1 mM DTT, 5% 
Glycerol and 5 mM Cl2Mg). Each protein’s 
expression was confirmed by Western blot as 
previously described (18). Supershifts assays 
were carried out using specific α-PPARα (sc-
9000), α-LXRα/β (sc-13068) and α-RXRα (sc-
553) antibodies in the reaction mix for 30 min on 
ice before adding the probe. DNA-protein 
complexes were resolved on a 6% (w/v) non 
denaturing polyacrylamide gels in 0.5x TBE 
buffer (1x TBE is 90 mM Tris, 90 mM boric acid 
and 1 mM EDTA). The dry gel was exposed 
overnight in an IP screen and analyzed in a 
FLA5000 (FUJIFILM).  
 
Total RNA preparation and RT-PCR.. Total 
RNA was isolated from hepatocytes by using 
Trizol reagent (Invitrogen). First-strand cDNA 
was synthesized from 1 µg of total RNA using a 
random hexamer and expand reverse 
transcriptase (Roche Diagnostics, Manheim, 
Germany). The cDNA was used as a template for 
quantitative PCR using Syber Green reagent 
(Applied Biosystem) and specific primers for rat 
and mouse Srebp1c (forward primer 5’-
CCATGGATTGCACATTTGAA-3’, reverse 
primer 5’-GGCCAGGGAAGTCACTGTCTT -
3’) or human SREBP1c (forward primer 5’-
CCATGGATTGCACTTTCGAA -3’, reverse 
primer 5’- GGCCAGGGAAGTCACTGTCTT -
3’). The amount of total cDNA in the sample was 
analyzed in the same reaction using specific 
primers for mouse Gapdh (forward primer 5’-
GTATTGGGCGCCTGGTCAC-3’, reverse 
primer 5’-AATCTCCACTTTGCCACTGCA-
3’), rat β-actin (forward primer 5’-
TTCACCACCCCAGCCATGT-3’, reverse 
primer 5’-GTGGTACGACCAGAGGCATACA-
3’) or human 36B4 (forward primer 5’-
AGATGCAGCAGATCCGCAT-3’, reverse 
primer 5’-GTTCTTGCCCATCAGCACC-3’) as 
a control. FAS (Hs00188012_m1) and ACC 
(Hs00172885_m1) mRNA expression levels 
were quantified using the ABI 7500 fast 
instrument and Taqman technology (Assays-on-
demand gene expression product; Applied 
Biosystems). 
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Chromatin Immunoprecipitation. ChIP assays 
were performed as previously described (19) 
using the isolated nuclei from the formaldehyde 
cross-linked human and rat hepatocytes. 
Immunoprecipitation was performed with the α-
PPARα (sc-9000), α-RXRα (sc553), α-SREBP1 
(sc-8984) and α-RNA pol II (sc-899) (Santa Cruz 
Biotechnology, Santa Cruz, U.S.A.) antibodies. 
Normal rat IgG (sc-2026) was employed as a 
negative control for rat hepatocytes. Purified 
samples were analyzed by PCR. The primers 
used to detect target sequences were as follows: 
Human DR1/LXRE site (SREBP1c promoter) 5'- 
GCCAGGACTTCTCTGCTTTG-3’ and 5'- 
GGGTTGGGGTTACTAGCGGACG-3’; Human 
SREBP1c coding region (exon 9) 5’-
GGCTGCTGCCCCCAGT-3’ and 5’-
GACAAAGAGAAGCACCAAGGAGAC-3’; 
Human HMGCR (promoter) 5'- 
ACGCTGATTTGGGTCTATGG-3’ and 5'- 
GTGTAAATGGCTCCGGTCAC-3’; Human α-
actin (coding region) 5'- 
CTTCTGCCCTCCGCAGCTGA-3’ and 5'- 
GTGAATGCCCGCCGACTCCA-3’; Rat LXRE 
site (Srebp1c promoter) 5’- 
CTGGCGCAGTTGCGGTTAAA-3’ and 5´- 
GCCGCGCCGCGCCCCAATAA- 3´, Rat SRE 
site (Srebp1c promoter), 5’- 
CTGCTGATTGGCCATGTGC-3’ and 5´- 
GCTACCCCTACAGCGTCCG-3´; Rat  Srebp1 
coding region  (exon 4) 5’- 
GCCCATCCACCGACTAGCAG-3’ and 5´- 
GGAACGGTAGCGCTTCTCAA - 3´and Rat β-
actin   (coding region), 5´- 
TTCACCACCCCAGCCATGT- 3´ and 5´- 
GTGGTACGACCAGAGGCATACA- 3´. PCR 
fragments were generated with a 5-min melting 
step at 94ºC, followed by 45 cycles of 
amplification (94ºC for 30 s, 56ºC for 30 s and 
72ºC for 45 s) and a terminal extension. Each 
ChIP assay was performed at least twice to 
ensure reproducibility. 
 
Confocal Microscopy. Human hepatocytes 
grown in 35 mm glass bottom dishes no. 1.5 
(MatTek Corp., Ashland, MA) were used for live 
cell imaging. Cells were treated for 24 h under 
basal conditions or with 1 μM GW7647, 100 nM 
insulin, or a combination of both. Cells were 
fixed in 4% PFA pH 7 for 10 min and washed 
three times with PBS 1X. Nile red staining was 
performed using the modified protocol described 
previously (20). Briefly, fixed cells were 
incubated for 4 h with 1 μg/ml of Nile Red 
solution and washed in PBS 1X overnight. 
Afterward, cells were stained for 10 min with 
DAPI 8 μg/ml to visualize cell nuclei. Confocal 
images were obtained with a Leica TCS SP2 
Spectral microscope and a 63X/1.40 NA oil 
objective (Leica Microsystems, Wetzlar, 
Germany). Fluorescence intensity was measured 
with the ImageJ program. 
 
Statistical analysis. Values are expressed as 
mean ± SD (n ranged from 3 to 5 independent 
experiments). Statistical significance was 
estimated with the Student’s two-tailed t-test for 
unpaired observations. A p-value of less than 
0.05 was considered significant. 
 
RESULTS 
 
Sequence alignment of rodents and human 
SREBP1c promoters. A comparative analysis of 
the human, rat, and mouse genomic sequences at 
the 5’ upstream position from the SREBP1c 
isoform transcriptional start site reveals a high 
degree of similarity, particularly in the first 300 
bp (Fig. 1). However, some critical differences 
along the promoter region can be identified. 
First, the human sequence presents an expansion 
of 67 bp that contains at least five SP1 binding 
sites. Second, the E-box present in the mouse and 
rat promoters is absent in the human sequence. 
Third, the rat and mouse promoters present a 
unique SRE binding site, whereas an additional 
SRE element is found 100 bp upstream in the 
human promoter, as previously described (10). 
Two human exclusive regulatory sequences were 
observed in the distal region: a previously 
described PDX1 binding site (21) and a DR1 
binding site predicted by an in silico analysis.  
 We first confirmed the identity of the 
basal transcription regulatory elements, which 
were predicted on the basis of the proximal 
promoter region’s similarity between species. A 
deletion analysis of 1500 bp of the human 
SREBP1c promoter cloned in a luciferase 
reporter vector was performed in transiently 
transfected rat primary hepatocytes. A construct 
containing 300 bp, which includes one SRE site, 
the NFY site and all the SP1 sites, was able to 
maintain almost 60% of the activity observed 
with the complete 1500 bp promoter luciferase 
construction (Fig. 2). The -520/+1 vector, which 
lacks only the PDX1 binding site, showed no 
diminished activity. Furthermore, a construction 
with a 158 bp deletion without the SRE2, the 
NFY and all the proximal SP1 binding sites, 
displayed no luciferase activity. This deletion 
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analysis indicates that the PDX1, DR1 and 
LXRE sites are not relevant for the human 
SREBP1c promoter’s basal activity in 
hepatocytes.  
 
Insulin regulation is mediated by the SRE and 
LXRE sites. The insulin-mediated regulation of 
the SREBP1 pathway has been extensively 
studied in recent years. This hormone is the most 
important factor to specifically regulate the 
SREBP1c isoform, which reflects the relevance 
of this protein in the interplay between glucose 
and lipid metabolism (3). Although it is clear that 
insulin activates the murine Srebp1c promoter by 
acting on SRE sites, and is mediated by SREBP 
itself, there has been some controversy about the 
relevance of LXRE sites in this regulation (10). 
In order to clarify this issue, we analyzed the 
insulin-mediated regulation of the human 
SREBP1c promoter in rat primary hepatocytes. 
The single and double mutants for all the 
relevant binding sites in the promoter were 
generated on the -1564/+1-luc construction. Each 
construct’s activity was studied under basal 
conditions or after 100 nM insulin stimulation by 
luciferase assays in transiently transfected rat 
hepatocytes. Insulin increased WT human 
promoter construction activation by 1.75 fold 
(Fig. 3A). The single and double SRE mutants in 
the human promoter abolished the insulin 
response. The same effect was seen in the single 
and double LXRE mutants, or in the 1c310 
construction which lacks both LXREs and one 
SRE binding site. This result suggests that 
human SREBP1c promoter regulation by insulin 
was mediated by both the SRE and LXRE 
elements in the liver, and that the absence of any 
of these sites abolishes SREBP1c activation. 
Deletion of the NFY binding site also led to a 
loss of insulin response, but this effect was 
probably associated with the diminished basal 
activity in this mutant.  
 
Both LXRE sites are necessary for complete 
promoter activation. Activation of the Srebp1c 
mouse promoter at the LXRE sites is mediated 
by LXR nuclear receptors, as previously shown 
(6). To study this regulation on the human 
promoter, we performed a luciferase assay in 
transiently transfected rat hepatocytes with 
various human SREBP1c-reporter vectors. The -
1564/+1-luc construction showed a more than 4-
fold activation in the presence of LXR synthetic 
agonist TO901371 (Fig. 3B). This activation 
lowered by 50% when one of the LXRE sites 
was deleted, and it was completely abolished 
when both sites were muted. The same effect 
was seen in the -310/+1 construct which does not 
contain the LXRE binding sites. The SRE double 
mutant and the NFY mutant displayed a normal 
LXR response in spite of their diminished basal 
activity. This experiment demonstrates that the 
two LXR binding sites are functional for the 
human SREBP1c promoter stimulatory effect of 
TO901317, and in the same way as in the rat and 
mouse promoters. 
 
The human SREBP1c promoter is activated by 
PPARα agonists. The in silico analysis of the 
human SREBP1c promoter predicted a DR1 
motif, recognized as a PPAR/RXR or a HNF4 
binding site according to the Motifviz and 
Matinspector programs, respectively. A 
comparative analysis with different databases 
revealed that the DR1 site present in SREBP1c is 
very similar to that of the active PPRE in the 
malic enzyme promoter’s regulatory region (22). 
Although there are several members of the 
PPARs family, PPARα is the most abundant in 
the liver. To evaluate the relevance of PPARα on 
the SREBP1c promoter regulation, we performed 
a reporter assay using rat hepatocytes transiently 
transfected with human SREBP1c luciferase 
constructs. The cells were treated with two 
PPARα agonists: WY14643 and GW7647. Both 
agonists increased the SREBP1c promoter 
activity of either the -1564/+1 or the -520/+1 
constructs. No activation was observed using the 
-310/+1-luciferase vector which lacks DR1 and 
both LXREs motifs (Fig. 4A).  
 Regulation of the SREBP1c expression 
by PPARα agonists was assessed in human 
hepatocytes primary culture by a quantitative 
PCR analysis after 24 h of treatment with 
GW7647. The SREBP1c expression significantly 
increased by 2-fold in the presence of the PPARα 
agonist (Fig. 4B). As expected, a similar effect 
was seen when cells were treated with 100 nM 
insulin for 24 h. Moreover, the PPARα agonist 
increased the insulin effect with more than a 7-
fold activation in the presence of both GW7647 
and insulin.  
 To determine whether the activation of 
SREBP1c by PPARα is due to its binding to the 
predicted DR1 site in the human promoter, we 
performed an EMSA assay using in vitro 
synthesized PPARα and RXRα proteins. A 
PPAR/RXR heterodimer was found to bind to 
the DR1 probe with partial competition in the 
presence of the anti-PPARα antibody and an 
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extinction of binding in the presence of the anti-
RXR antibody. When adding synthesized RXRα 
protein alone, the presence of a single retarded 
band indicated that an RXR homodimer was also 
capable of binding to this sequence in vitro (Fig. 
4C). An EMSA assay was performed using a 
PPRE probe as a positive control and a mutated 
PPRE as a negative control; the expression of 
each recombinant protein was confirmed by 
Western blot analysis (data not shown). 
 The gel shift data were supported with a 
ChIP assay using human primary hepatocytes. 
Monolayer cells were fixed and total chromatin 
was extracted 24 h after incubation with 1 μM 
GW7647. The binding of PPARα to the 
SREBP1c promoter was analyzed. An RNA pol 
II antibody was used as a control of the active 
gene expression, while an RXRα antibody was 
used as a positive control. After DNA 
purification, we analyzed the binding of PPARα, 
RXRα and RNA pol II by PCR. Both PPARα 
and RXRα were seen to bind to the SREBP1c 
promoter (Fig. 4D). We analyzed the binding of 
PPARα and RXRα to the HMGCR promoter, 
which contains an active PPRE and, as expected, 
presented a positive binding to both proteins.  No 
enrichment was seen when we used primers to 
amplify the α-actin or the SREBP1c coding 
region. The -RNA polymerase antibody mainly 
precipitated in the coding chromatin fragments of 
HMGCR and SREBP1c, and was absent in α-
actin, which was not expressed under the 
experimental conditions (Fig. 4D). 
 
LXRE-mediated activation of the SREBP1c 
promoter by PPARα agonists. Considering that 
the human SREBP1c expression was induced by 
PPARα agonists in human hepatocytes and that 
the SREBP1c promoter was able to bind to 
PPAR/RXR heterodimers in vitro and in vivo, we 
analyzed the regulation of the human SREBP1c 
promoter in the presence of the PPARα and 
RXRα overexpressions. The overexpression of 
RXR alone activated the promoter in rat primary 
hepatocytes, while the PPARα overexpression 
was only able to produce a slight, but non 
significant, increase in SREBP1c activity. It was 
the co-expression of both proteins that brought 
about the greater activation of the human 
SREBP1c promoter (Fig. 5A). To evaluate 
whether SREBP1c activation was present only in 
the human promoter, we performed the same 
analysis using a rat Srebp1c promoter luciferase 
reporter vector. An unexpected result was 
obtained given that the PPAR/RXR heterodimer 
overexpression also activated the rat Srebp1c 
promoter (Fig. 5A).  
 Taking into account the activation of the 
rat promoter by PPAR/RXR and the absence of a 
DR1 binding site in the sequence, we considered 
an LXRE binding site implication in this 
activation. We performed a shift assay to analyze 
the binding of PPAR/RXR and LXR/RXR to two 
separate probes that contained all the SREBP1c 
promoter LXRE sites (Fig. 5B), and observed an 
in vitro binding of the LXR/RXR heterodimer to 
both probes (lanes 4 and 9), which was partially 
competed by the anti-LXR antibody (lanes 5 and 
10). Surprisingly, when we incubated both 
probes in the presence of PPAR and RXR, a 
retarded band appeared (lanes 1 and 6), which 
was totally competed with the α-RXR antibody 
(lanes 3 and 8). In the presence of the α-PPARα 
antibody however, we observed competition for 
the PPAR/RXR heterodimer only with the 
LXRE2 probe (lane 7). This result suggests that 
the PPAR/RXR heterodimer is capable of 
binding in vitro to the LXRE2 site, but not to the 
LXRE1 site. Moreover, the PPARα agonist 
significantly increased the liver SREBP1c 
endogenous expression in rat and mouse cultured 
hepatocytes treated with 1 μM GW7647 for 24 h 
(Fig. 5C).   
 To determine the in vivo binding of 
PPARα to the rat Srebp1c promoter, we 
performed a ChIP assay using rat primary 
hepatocytes. Monolayer cells were fixed and 
total chromatin was extracted 24 h after 
incubation with 1 μM GW7647. The binding of 
PPARα and SREBP1 to the Srebp1c promoter 
was analyzed. An RNAse pol II antibody was 
used as a control of the active gene expression. A 
positive binding of PPARα to the SREBP1c 
promoter’s LXRE region was observed (Fig. 
5D). SREBP1 binding was detected mainly in the 
SRE binding site together with RNA pol II, 
which also precipitated with the SREBP1c and β-
actin-coding chromatin fragments. No PPARa 
binding was observed in the absence of GW7647 
(data not shown).  
   
Cross-regulation between PPAR and LXR on the 
SREBP1c promoter. We have demonstrated 
above an interaction between PPARα and the 
LXRE binding site in the SREBP1c promoter. 
We next studied the cross-regulation between 
LXR and PPARα, which participate together in 
SREBP1c activation. We evaluated the effect of 
LXR knocking on human SREBP1c promoter 
activity by transfecting WT and LXRα/β double 
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knockout (DKO) mouse hepatocytes with the 
human SREBP1c reporter promoter construct. 
The -1564/+1 construct of the human SREBP1c 
promoter was activated in the presence of the 
LXR and PPARα agonists, TO901317 and 
GW7647, respectively. The LXR-mediated 
response was abolished in the DKO hepatocytes 
and was rescued when an LXRα expression 
vector was added to the transfection mix, as 
expected. However, we observed a diminished 
but still significant activation of the human 
promoter in the DKO hepatocytes in the presence 
of 1 μM GW7647, with a normal response noted 
in the presence of the exogenous LXRα protein 
(Fig. 6A).  
 A luciferase assay with the WT and 
LXRE double mutant constructions of the human 
SREBP1c promoter was performed to further 
analyze the interaction between PPARα and 
LXR. This assay revealed that TO901317 
activation was eliminated in the double LXRE 
mutant construction, but GW7647 significantly 
activated both the WT and the mutant 
constructions. However, the double LXRE 
mutant led to diminished activation in the 
presence of the PPARα agonist if compared to 
the WT. This result corroborates the data 
obtained in DKO mice, demonstrating that LXR 
is necessary for SREBP1c promoter maximum 
activation in the presence of a PPARα ligand 
(Fig. 6B). Furthermore, a synergic effect with 
combined LXR and PPARα agonists was 
observed in the human promoter, but not in the 
rat promoter (Fig. 7A). This difference between 
species was also observed when using the 
PPARα and LXR overexpressions (data not 
shown). To corroborate this synergic effect 
produced by the LXR and PPARα agonists, we 
analyzed the activation of endogenous SREBP1c 
in cultured human hepatocytes treated with the 
respective agonists. The SREBP1c gene 
expression was activated 2-fold in the presence 
of 1μM GW7647. A concentration of 10 nM 
TO901317 activated SREBP1c to the same 
extent, and boosted GW7647 activation with a 
5.5-fold induction in the presence of both 
agonists (Fig. 7B).  
 
Lipogenesis activation by PPARα agonists. To 
evaluate the effect of the PPARα-mediated 
activation of SREBP1c on the lipogenic 
pathway, we analyzed the expression of fatty 
acid synthase (FAS) and acetyl-coA carboxylase 
(ACC) lipogenic genes. GW7647, insulin, and 
TO901317 slightly activated both FAS and ACC 
in human hepatocytes; an additive effect was 
seen with insulin and GW7647, and also with 
GW7647 and TO901317 (Fig. 8A and B). This 
effect on GW7647-mediated insulin lipogenic 
potentiation was confirmed by confocal 
microscopy. Freshly isolated human hepatocytes 
were treated as indicated previously, and were 
subjected to Nile red and DAPI staining. Under 
these conditions, we were observed a cytosolic 
lipids accumulation in the presence of 100 nM 
insulin with a synergic effect when GW7647 was 
also present (Fig. 8B). Fluorescence intensity in 
the insulin- and GW7647-treated hepatocytes 
was significantly enhanced (data not shown).    
  
DISCUSSION 
 
 Insulin and lipids mediators are signaling 
molecules that regulate cellular responses in a 
wide range of physiological and pathological 
nutritional disorders. The SREBP1c 
transcriptional factor is a convergence point from 
starving to post-prandial phases. To coordinate 
these signals, the promoter region of SREBP1c 
contains multiple and complex regulatory 
elements modulated by cholesterol, fatty acids 
and carbohydrates (11). In this report, we have 
identified the most relevant regulatory sequences 
in the human SREBP1c promoter structure. 
 We have clearly demonstrated that the 
insulin-responsive elements in the SREBP1c 
promoter involve both LXRE and SRE binding 
sites, which are essential for maximum activation 
in hepatocytes. Different binding sites, such as 
LXRE, SRE, SP1 and NFY, have been shown to 
be involved in the regulation of the mouse and 
rat Srebp1c promoters in different cell lines 
during a full insulin response (15). It is important 
to stress that SP1 and NFY are responsible for 
almost 60% of basal activity; this sometimes 
makes it difficult to elucidate their implication in 
insulin activation. An SRE binding site 
implicates an auto-regulatory loop mediated by 
SREBP1c itself and by other SREBP family 
members. The presence of a second active SRE 
binding site in the human promoter suggests that 
this loop plays an important role in human 
metabolism regulation. Studies performed in 
skeletal muscle have demonstrated that this loop 
is more relevant for insulin regulation than LXR 
(10). However, our results prove the essential 
role of LXR signaling in insulin regulation in 
hepatocytes. Different mechanisms have been 
described to be implicated in the insulin 
mediated activation of LXR and its target genes. 
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In addition, insulin has been seen to activate the 
LXR expression in the liver (23), while others 
have hypothesized that insulin may stimulate the 
production of an oxygenated sterol ligand for this 
nuclear receptor (13). Furthermore, physiological 
glucose concentration activates LXR in the liver 
and induces the expression of LXR target genes, 
whose efficacy is similar to that of oxysterols, 
the well-known LXR ligands (24). LXR could, 
therefore, be a transcriptional switch that 
integrates hepatic glucose metabolism and fatty 
acid synthesis.  
 Many aspects of hepatic lipid 
metabolism are under the transcriptional control 
of PPAR. It is well-established that an impaired 
PPAR function is associated with hepatic lipid 
accumulation. Moreover, synthetic agonists for 
PPARα have been explored for the treatment of 
fatty liver disease (25). The discovery of a DR1 
putative binding site in the human promoter 
prompted us to study the human SREBP1c 
promoter’s response to PPARα ligands. We 
found a positive response to WY14643 and 
GW7647 agonists together with activation in the 
presence of an exogenous PPAR expression. 
Moreover a synergic effect was observed in the 
presence of insulin or LXR agonists. PPARα 
seems to be an activator of the SREBP1c 
promoter in vivo, as predicted by chip-chip 
analyses (26).  
 Crosstalk between PPAR and LXR at the 
transcriptional level has been previously 
demonstrated. An active PPRE element present 
in the LXRα promoter region is able to respond 
to PPAR agonists (27). Given the fact that there 
are two LXRE active sites in the SREBP1c 
promoter, we considered the possibility of an 
indirect activation of this promoter mediated by 
LXRα activation. However, SREBP1c promoter 
activation in the presence of the PPARα/RXR 
heterodimer was seen in either hepatocytes from 
double LXR knockout mice (DKO) or rat 
hepatocytes transfected with the LXRE double 
mutant luciferase construction. These 
experiments demonstrate a direct activation 
mediated by PPAR itself.  
 The effect of the PPARα nuclear 
receptor on the control of Srebp1c mouse 
promoter activity has been previously studied 
(9). The authors showed that PPARα inhibited 
the mouse Srebp1c promoter’s LXR-mediated 
activation in HEK293 and HepG2 cells; 
moreover, they observed no activation in rat 
hepatocytes treated with WY14643 . The authors 
suggested that this inhibition was mediated by 
the sequestration of RXR avoiding the LXR-
mediated activation. This discrepancy may relate 
to the use of fasted mice in Yosikawa’s study. 
König et al have also shown that PPAR 
agonists reduce triglycerides synthesis in rat 
hepatoma cells, which is partially caused by 
inhibited SREBP1 activation (28). The above 
experiments were performed under low glucose 
conditions to mimic the fasted condition. 
However, our experiments were performed in 
cells maintained at high glucose concentrations 
or in hepatocytes obtained from ad libitum-fed 
animals. Our results suggest that PPAR 
mediatedSREBP1c promoter activation is 
dependent on the presence of the LXR nuclear 
receptor, and probably on nutritional status. 
Recently, Chakravarhy et al. have identified a 
physiologically relevant endogenous ligand for 
PPAR in the liver that induces the expression 
of those genes involved in fatty acid metabolism, 
but only in the presence of active fatty acid 
synthase (29). Furthermore, the SREBP1c 
mRNA levels were lower in the livers of 
PPARα-null mice than in the WT mice (30). 
Accordingly, the level of SREBP1c significantly 
increased in fenofibrate-treated WT mice (31), 
but not in PPARα-null mice (32). Thus it is 
feasible to hypothesize that PPARα gene 
expression regulation in general, and the 
SREBP1c expression in particular, may depend 
on an acting ligand nature.  
 PPARα has been shown to govern the 
expression of numerous genes involved in fatty 
acid oxidation, ketogenesis, gluconeogenesis, 
cholesterol catabolism and lipoprotein 
metabolism (33). However, the data obtained 
from transgenic mice (34) and our results 
achieved with human hepatocytes report that 
PPAR does not merely serve as a 
transcriptional activator of fatty catabolism, but 
plays a much broader role in lipid metabolism. 
An important question to clarify is why a 
transcription factor, whose primary role is to 
coordinate fatty acid oxidation in the starved 
state, is required to facilitate fatty acid synthesis 
during the re-feeding period. We have shown 
that PPAR agonists cooperate with insulin to 
induce hepatic lipid synthesis. Our results also 
demonstrate that LXR is essential for SREBP1c 
regulation by insulin through its LXR elements 
present in the promoter. Moreover, the maximum 
effect of PPAR is obtained when the LXR 
element remains unmodified. PPAR may be 
required for the production of an endogenous 
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LXR ligand. In line with this, the original 
PPAR dependence of insulin action in 
PPARdeficient mice was abolished under 
conditions in which LXR activation was not 
limiting (35).  
 Important differences between rodents 
and humans have been previously demonstrated 
in terms of gene regulation by PPAR and LXRs, 
especially in the field of macrophage 
homeostasis (36). It is important to bear in mind 
not only that the expression levels of PPAR and 
LXR can differ between humans and mice, but 
levels of RXR expression may vary and could 
influence the activity of both LXR and PPAR, 
and their crosstalk (7). 
 Ours results provide an insight into the 
role of the insulin-, LXR-, and PPAR-mediated 
regulation of human SREBP1c and its relation 
with nutritional status. PPARα and LXR act as 
lipid-glucose sensors and bind to ligands 
deriving from either intracellular metabolism or 
dietary lipids. Endogenous ligands for PPAR 
include fatty acids and eicosanoids, whereas 
metabolites of oxidized cholesterol activate 
LXRs. Moreover, it has been demonstrated there 
is no single endogenous ligand for PPAR, thus 
PPAR could play a role as a nutritional status 
sensor in the cell to regulate the SREBP1c 
dependent pathway by controlling the fasting/fed 
transition. 
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FIGURE LEGENDS 
 
 Figure 1. Sequence analysis of the 5´ flanking sequence of the human SREBP1c 
promoter. Sequence alignment of the proximal promoter region of human, rat and mouse SREBP1c, 
including the transcriptional start site (bold letters). A schematic representation of previously 
demonstrated binding sites in mice and rats, and the homolog sites in the human sequence are shown. 
Human specific predicted binding sites are also shown. 
 Figure 2. Identification of the minimal human SREBP1c promoter region. Serial of 
luciferase reporter constructs containing various lengths of the human SREBP1c promoter, from -1564 
to +1, were analyzed in primary culture rat hepatocytes. The d158-luc construction has a deletion of 
158 bp, which contains NFY, SRE2, and multiple SP1 sites corresponding to the region responsible 
for basal activity in mice and rats. Firefly and Renillla luciferase activities were measured in cell 
lysates. The results represent relative Firefly/Renilla luciferase activities by considering the -1564/+1 
construct as 100% fold activation. Bars represent the mean ± SE of four separate experiments. 
 Figure 3. Nutritional regulation of the human SREBP1c promoter. Insulin- and LXR-
mediated regulation of the human SREBP1c promoter were analyzed using -1564/+1-luc (1c1500), -
310/+1-luc (1c310) plasmids or mutants of the different cis-elements in the-1564/+1-luc vector. The 
relevance of each predicted binding site for insulin and TO901317 (LXR agonist) regulations was 
analyzed by luciferase assays. Activities of the WT and mutated constructs transfected in rat primary 
hepatocytes under basal conditions (gray bars) and 100 nM insulin (black bars), (A) or under basal 
conditions (gray bars) and 10 μM TO901317 (black bars) (B), are shown. The results represent 
relative Firefly/Renilla luciferase activities (RLU) considering the wild-type construct under basal 
conditions as 100% fold activation. Values are the mean ± SE of four separate experiments. 
Differences between the control and the TO901317 treatment significantly differ for all the 
constructions except for dmLXRE and 1c310 (* p<0.05; ** p<0.01). A scheme of the predicted 
binding sites in the human promoter is shown. 
 Figure 4. PPAR regulates human SREBP1c promoter activity. A- PPARdependent 
regulation of the SREBP1c promoter was analyzed by luciferase assays using the -1564/+1-luc 
(1c1500), -520/+1-luc (1c520) and -310/+1-luc (1c310) constructs in the presence of WY14643 (WY) 
or GW7647 (GW) as selective PPARα agonists. Activities of the promoter constructs transfected in 
rat primary hepatocytes under basal conditions (black bars), 30 μM WY (white bars) or 1M GW 
(gray bars) are shown. The results represent relative Firefly/Renilla luciferase activities considering 
the wild-type construct under basal conditions as the reference value. Values are the mean ± SE of 
four separate experiments. B- The endogenous SREBP1c expression in cultured human hepatocytes 
was analyzed by quantitative PCR. Cells were seeded under basal conditions (control) or treated with 
1 M GW7647 (GW) and/or 100 nM insulin. Total RNA was extracted 24 h after treatment and 
cDNA was synthesized by reverse transcriptase. The relative amount of the SREBP1c/36B4 
expression was determined in each condition by taking the basal condition as the reference value. The 
results are the mean ± SE of three separate experiments. Differences between the control and the 
treatments were statistically significant. C- Analysis of PPAR binding in vitro to the SREBP1c 
promoter. EMSA was performed with recombinant human proteins incubated with 32P-oligonucletide 
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encoding for the DR1 element of the human SREBP1c promoter. PPAR or RXR antibodies 
were used for the supershift assays. The complete EMSA gel, (left panel) shows that an equal amount 
of the probe was loaded in all the lanes. D- Analysis in vivo of PPAR binding to the SREBP1c 
promoter. The ChIP assay was performed in human hepatocytes treated with 1μM GW7647. 
Immunoprecipitation of samples was performed with the α-PPARα antibody. A positive control of 
transcriptionally active genes was performed using the α-RNA polII antibody and a negative control 
with no antibody. An α-RXR antibody was used as a positive control for the PPARα activated 
promoters. An analysis of the HMGCR gene was used as a positive control for PPARα and RXR 
binding. The α-actin primers were used as negative control for all the antibodies. The results are 
representative of the PCR fragments analysed by agarose gel electrophoresis of two independent 
experiments. 
  
 Figure 5. PPARα-mediated SREBP1c activation through an LXRE binding site. A-
PPARα-mediated regulations of the human and rat SREBP1c promoters were analyzed using rat 
primary hepatoctyes. Cells were transiently transfected with a plasmid containing 1500 bp of a human 
or rat SREBP1c promoter sequence linked to the luciferase reported plasmid pGL3-basic together 
with the a) PPARα, b) RXRα, and c) PPARα and RXRα expression vectors.  An empty vector was 
used to normalize the amounts of total transfected DNA. Firefly and Renillla luciferase activities were 
measured in cell lysates. The results represent relative Firefly/Renilla luciferase activities by 
considering the empty vector condition as 100% fold activation. Values are the mean ± SE of four 
separate experiments. B-EMSA was performed with the recombinant human proteins incubated with 
32P-oligonucletide encoding for LXRE1 and LXRE2 sites. α-PPARα, α-LXRα or α-RXRα antibodies 
were used for the supershift assays. C- The endogenous SREBP1c expression in cultured rat and 
mouse hepatocytes was analyzed by quantitative PCR. Cells were seeded under basal conditions 
(control) or treated with 1M GW7647 (GW). Total RNA was extracted 24 h after treatment and 
cDNA was synthesized by reverse transcriptase. The relative amount of the SREBP1c/GAPDH 
expression was determined under each condition by taking the basal condition as the reference value. 
The results are the mean ± SE of three separate experiments. D-The ChIP assay was performed with 
rat primary hepatocytes. Immunoprecipitation of samples was performed with the α-PPARα and α-
SREBP1 antibodies. A positive control of the transcriptionally active genes was performed using the 
α-RNA polII antibody, and a negative control was normal rat IgG and no antibody. The results are 
representative of the PCR products analyzed by agarose electrophoresis of three independent 
experiments. 
 Figure 6. Cross-regulation between PPAR and LXR on the SREBP1c promoter. A- 
Human SREBP1c promoter regulation was analyzed using the wild-type (WT) and LXRα/LXRβ 
double-mutant mice (DKO) primary hepatocytes transfected with the -1564/+1-luc vector either with 
or without an LXRα expression vector. An empty vector was used to normalize the amounts of total 
transfected DNA. Firefly and Renillla luciferase activities were measured in cell lysates after 
treatment with 10 μM TO901317 (TO; upper panel) or 1 μM GW7647 (GW; lower panel) for 24 h. 
The results represent relative Firefly/Renilla luciferase activities by considering the control condition 
as 100% fold activation. Values are the mean ± SE of four separate experiments. B-Luciferase assay 
was performed in the rat hepatocytes transfected with -1564/+1-luc (WT) and LXRE double mutant-
luc (dmLXRE). Cells were seeded under basal conditions (control) or treated with 1 M GW7647 
(GW) or 10 M TO901317 (TO). The results represent relative Firefly/Renilla luciferase activities by 
considering the control condition for each construction as 100%. Values are the mean ± SE of three 
separate experiments.  
 Figure 7. Additive effect of PPAR and LXR on SREBP1c promoter regulation. A-The 
additive PPARα- and LXR-mediated regulations of human and rat SREBP1c promoters were 
analyzed using rat primary hepatoctyes. Cells were transiently transfected with a plasmid containing 
1500 bp of the human or rat SREBP1c promoter sequence linked to the luciferase reported plasmid 
pGL3-basic treated for 24 h with 1 μM GW7647 (GW) and/or 10 nM TO901317 (TO). Firefly and 
Renillla luciferase activities were measured in cell lysates. The results represent relative 
Firefly/Renilla luciferase activities by considering the control condition as 100% fold activation. 
Values are the mean ± SE of four separate experiments (* p<0.05).  B- The endogenous SREBP1c 
  13
expression in the cultured human hepatocytes was analyzed by quantitative PCR. Cells were seeded 
under basal conditions (control) or treated with 1 M GW7647 (GW) and/or 10 nM TO901317 (TO). 
Total RNA was extracted 24 h after treatment and cDNA was synthesized by reverse transcriptase. 
The relative amount of the SREBP1c/36B4 expression was determined under each condition by 
considering the basal condition as the reference value. The results are the mean ± SE of three separate 
experiments Differences between the control and the treatments were statistically significant. 
 Figure 8. Lipogenic effect of PPARα agonists in the liver. A- The endogenous FAS and 
ACC expression in human cultured hepatocytes were analyzed by quantitative PCR. Cells were 
seeded under basal conditions (control) or treated with 1 M GW7647 (GW), 10 nM TO901317 (TO), 
100 nM insulin (Ins), or with a combination of GW7647 with TO901317 or insulin. Total RNA was 
extracted 24 h after treatment and cDNA was synthesized by reverse transcriptase. The relative 
amount of the SREBP1c/36b4 expression was determined under each condition by considering the 
control condition as the reference value. The results are the mean ± SE of three separate experiments. 
(*<0.05). B-Lipids accumulation in human hepatocytes was analyzed by Nile red staining under a 
confocal microscope. The images are representative of at least 10 different images under each 
condition. All images were obtained under the same zoom, wavelength and intensity conditions.  
 
 
 
 
 
 
 
 
        TTGCTGCTGCCATTCGATGCGAAGGGCCAGGAGTGGGTAAACTGAGG-CTAAAATGGTCC -438
        TTGCTGCTGCCATTCAATGCGAAGGGACAGAAGTGGGTAAACTGAGG-CTAAAATTGGCC -422
        TCCCTTCTACCATTCGACGCC-AGGGA-GATAATGACTGTCCTGTTTTCTGGAGGAGTAA -538
        *  ** ** ****** * ** ****     * **  *   ***    **  *   *   
        AGGCAAGTTCTGGGTGTGTGCGAACGAACCAG--CGGTGGGAACACAGAGCTTCCGGGAT -380
        ATACTAGTTCTGGGTGTGTGCGAA----CCAG--CGGTAGAAACACAGAGCTTCCGGGAT -388
        ACGGAGGGTTGGAGCGGTTAAGGCTCGCTCAGGGTGCCAGCGAACCAGTGATTTCGAACA -478
        *     * *  * * *  *  *       ***   *   *  *  *** * ** **    
        CAAAGCCAGACGCCGTCCGGATTCCGGACCCAGGCTCTTTTCGGGGA--------TGGTT -328
        CAGAGCCCGCCGCTGTCCAGATTCCGAACCCAGGCACTTCTGGGGGGGGGGGGGGTGGTT -328
        CAGAGTTC--TGGTGTGTTGGGCCAGGACTT---CTCTGCTTTGACCC--------TTTA -434
        ** **      *  **   *   * * **     * **  *  *              * 
        GCCTGTGCGGCAGGGGTTGGGACGACAGTGACCGCCAGTAACCCCAGCGCGCGCTGGCGC -268
        GCCTGTGCGGCAGGGGCTGGGACGGCAGTGACCGCCAGTAACCCCGGCGCGCGCTGGCGC -268
        ACGAAGGGGGCGGGAGCTGAGG-GCCAGTGACCGCCAGTAACCCCGGCAGACGCTGGCAC -375
         *    * *** ** * ** *  * ******************** **   ******* *
        AGACGCGGTTAAAGGCGGACGCCCGCTAGTAACCCCGGCCCCATTCAGAGC-ACCGGGAG -209
        AGTTGCGGTTAAAGGCGGACGCCCGCTAGTAACCCCGGCCCCATTCAGAGC-ACCCGGTG -209
        CGAGCGGGTTAAAGGCGGACGTCCGCTAGTAACCCCAACCCCATTCAGCGCCGCGGGGTG -315
         *    *************** **************  ********** **  *  ** *
        AAACCCGAGCTGCCGCCGTCGGGGGTGGGCGGGGC-----------------CCTAATGG -166
        AAACCCGAGCTGCTGCCGTCGGGGGTGGGCGGGGC-----------------CTTATTGG -166
        AAACTCGAGCCCCCGCCGCCGTGGGGAGGTGGGGCGGGGGCCGGGGCCGGGCCCTAGCGA -255
        **** *****  * **** ** ***  ** *****                 * **  * 
        GGCG-CGGCGCGGCTGCTGATTGGCCATGTGCGCTCACCC-------------------- -127
        GGCG-CGGCGCGGCTGCTGATTGGCCATGTGCGCTCACCC-------------------- -127
        GGCGGCAGCGCGGCCGCTGATTGGCCGCGCGCGCTCACCCCATGCCCGGCCCGCAGCCCC -195
        **** * ******* ***********  * **********    
        GAGGGGCGGGGCACGGAG------------------------------------------ -109
        GAGGGGCGGGGCACGGGG------------------------------------------ -109
        GAAGGGCGGGGCGGGGCGGGACCTGCAGGCGGGGCGGGGCTGGGGCGGGGCTGGGGGCGG -135
        ** ********* ** * 
        -------------------------GCGATCGGCGGGCTTTAAAGCCTCGCGGGGCCTGA -74
        -------------------------GCGCTCAGCGGGCTTTAAAGCCTGGCGGGGCCTGA -74
GGCGGGGCGGGGCGGGCGCGCCGCAGCGCTCAACGGCTTCAAAAATCCGCCGCGCCTTGA -75
                                 *** **  ***  *  ***  *   ** * * ***
        CAGGTGAAATCGGCGCGGA-AGCTGTCGGGGTAGCG-TCTGCACGCCCTAGGGGCGGGGC -16
        CAGGTGAAATCAGCGCGGA-CGCTGTAGGGGTAGCG-TCTGCACGCCCTAGGGGCGGGGC -16
        CAGGTGAAGTCGGCGCGGGGAGGGGTAGGGCCAACGGCCTGGACGCCCCAAGGGCGGG-C -16
        ******** ** ******   *  ** ***  * **  *** ****** * ******* *
        GCGGACCACGGAGCCATGGATTGCACATTTGAAG----------- 19
        GCGGACGACGGAGCCATGGATTGCACATTTGAAG----------- 19
    GCAGATCGCGGAGCCATGGATTGCACTTTCGAAGGTATTTTTGGA 30
** **   ****************** ** ****           
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